Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

s0122159

—

aa875dd9-2f03-5317-b839-bd4f9c4042b7

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.500
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • TNFA_SIGNALING_VIA_NFKB+0.500
  • APICAL_SURFACE+0.400
  • CHOLESTEROL_HOMEOSTASIS+0.400
  • COAGULATION+0.400
  • ESTROGEN_RESPONSE_EARLY+0.400
  • ESTROGEN_RESPONSE_LATE+0.400
  • INFLAMMATORY_RESPONSE+0.400
  • NOTCH_SIGNALING+0.400

Top 10 suppressed

  • DNA_REPAIR-0.200
  • E2F_TARGETS-0.200
  • MYC_TARGETS_V1-0.200
  • MYC_TARGETS_V2-0.200
  • OXIDATIVE_PHOSPHORYLATION-0.200
  • FATTY_ACID_METABOLISM-0.100
  • G2M_CHECKPOINT-0.100
  • MITOTIC_SPINDLE-0.100
  • SPERMATOGENESIS-0.100
  • ADIPOGENESIS+0.000

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1BS_TK84K675
brain-umap@2
high-grade glioma—0.908
2BS_77CDMEY4
brain-umap@2
Ganglioglioma—0.905
3BS_0QYS36NR
brain-umap@2
Ependymoma NOS—0.896
4b556b718-38cf-498d-94c7-4e240fe57d48
melanoma-umap@29
——0.896
5SRR10900559
melanoma-umap@29
——0.893
6TCGA-BA-5557-01A-01R-1514-07
head-neck@1
——0.893
7BS_ZVZDDW2G
brain-umap@2
pleomorphic xanthoastrocytoma(PXA)—0.889
8SRR10900576
melanoma-umap@29
——0.889
9s_150324_1a
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.887
10BS_0QYS36NR
medullo-epn-umap@date-based
EPNEPN Tumor0.884

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 35 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.500Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.500Inavolisib— uncovered
APICAL_SURFACE0.400Temsirolimus— uncovered
CHOLESTEROL_HOMEOSTASIS0.400Remibrutinib— uncovered
COAGULATION0.400Binimetinib— uncovered
ESTROGEN_RESPONSE_EARLY0.400Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.400Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.400Idelalisib— uncovered
NOTCH_SIGNALING0.400Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.400Inavolisib— uncovered
ANDROGEN_RESPONSE0.300Inavolisib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
APOPTOSIS0.300Idelalisib— uncovered
COMPLEMENT0.300Inavolisib— uncovered
HEDGEHOG_SIGNALING0.300Inavolisib— uncovered
HYPOXIA0.300Idelalisib— uncovered
IL2_STAT5_SIGNALING0.300Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.300Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.300Idelalisib— uncovered